Abstract:The original synthesis of dopamine in the laboratories of H.E. Dale in South London, followed some 50 years later by the seminal mapping of the mesencephalic dopamine (DA) pathways into ramifying mesostriatal, mesolimbic and mesocortical projections, the identification of several DA receptors and their signalling pathways, and the discovery of phasic and tonic modes of dopaminergic activity, have led to important questions about the functions of this modulatory neurotransmitter. The triadic division of these projections has suggested discrete and even parallel functions in movement (eg, Parkinson9s disease, dorsal striatum), reward (eg, drugs of abuse, nucleus accumbens) and cognition (eg, schizophrenia and attention deficit/hyperactivity disorder (ADHD), prefrontal cortex). However, several lines of evidence show that this division to be artificial, it also being important to consider interactions between prefrontal and striatal systems, between the various sectors of the striatum itself, and even its component “direct” and “indirect” pathways. This lecture will provide several examples of how work performed in experimental animals has informed these functional considerations, while also having profound implications for understanding the functions of dopamine in health and disease. A prime example is the discovery that prefrontal cortical dopamine modulates cognitive functions such as working memory, which our own work has suggested to be a consequence of stabilising representations of the world via dopamine D1 receptor actions. This contrasts with findings that striatal dopamine often serves to promote behavioural switching, as occurs for example in Parkinson9s disease, ADHD and stimulant abuse following dopaminergic therapy with l-dopa, methylphenidate, and a D2/3 agonist, respectively. The hypothesis that there exist optimal levels of dopamine activity for efficient cognitive functioning in the prefrontal cortex also has applicability in the sub-cortical brain, based for example on the discovery that optimal titration of dopaminergic therapy for motor function in Parkinson9s disease can lead, not only to cognitive enhancement, but also behavioural dysregulation in certain domains, possibly arising as a consequence of an “over-dosing” of ventral striatal dopamine pathways with probable motivational consequences. Such a motivational role is consonant with the discovery that rewarding effects of psychomotor stimulant drugs such as cocaine and amphetamine were mediated by dopamine-dependent functions of the nucleus accumbens in rats. Recent work has shown that addiction to such drugs is predicted by individual differences in the propensity for impulsive behaviour, associated with variations in dopamine receptor number in the ventral striatum. This impulsivity may reflect an aberrant engagement of pavlovian approach behaviour. However, work in animals has suggested that during the addictive process, there is a shift in control of drug-seeking behaviour from the ventral to dorsal striatum that is consistent with a role for dopamine in stimulus-response habit learning. Implications for recent findings in chronic drug abusers will also be discussed.

S.27.03 Catecholamines and Fronto-Striatal Circuitry in ADHD: Human Studies and Translational Models

Prefrontal Cortical Α2a-Adrenoceptors and a Possible Primate Model of Attention Deficit and Hyperactivity Disorder

The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/Hyperactivity Disorder

Serotonergic and Adrenergic Neuroreceptor Manipulation Ameliorates Core Symptoms of ADHD through Modulating Dopaminergic Receptors in Spontaneously Hypertensive Rats

Enhanced Glial Reaction and Altered Neuronal Nitric Oxide Synthase Are Implicated in Attention Deficit Hyperactivity Disorder

[Advances in the Pathophysiology and Drug Discovery of Novel Therapeutics for Attention-Deficit/hyperactivity Disorder]

Modulation of High Impulsivity and Attentional Performance in Rats by Selective Direct and Indirect Dopaminergic and Noradrenergic Receptor Agonists

Animal Models of ADHD.

Adaptive Aspects of Impulsivity and Interactions with Effects of Catecholaminergic Agents in the 5-Choice Serial Reaction Time Task: Implications for ADHD

The mesocortical dopaminergic system cannot explain hyperactivity in an animal model of attention deficit hyperactivity disorder (ADHD)- Spontaneously hypertensive rats (SHR)

Cognitive Neuroscience of Attention Deficit Hyperactivity Disorder (ADHD) and Its Clinical Translation

Comparative Psychopharmacology of Methylphenidate and Related Drugs in Human Volunteers, Patients with ADHD, and Experimental Animals

Phasic dopamine signals are reduced in the spontaneously hypertensive rat and increased by methylphenidate

GL.01 Dopamine in Health and Disease

Neurobehavioral Mechanisms of Impulsivity: Fronto-striatal Systems and Functional Neurochemistry

From neurons to brain networks, pharmacodynamics of stimulant medication for ADHD

A Positron Emission Tomography Study of Nigro-Striatal Dopaminergic Mechanisms Underlying Attention: Implications for ADHD and Its Treatment.

Cross‐species Studies of Cognition Relevant to Drug Discovery: a Translational Approach

Chemical Neuromodulation of Frontal-Executive Functions in Humans and Other Animals

Comparison of SHR, WKY and Wistar rats in different behavioural animal models: effect of dopamine D1 and alpha2 agonists

Noradrenergic Versus Dopaminergic Modulation of Impulsivity, Attention and Monitoring Behaviour in Rats Performing the Stop-Signal Task